THC Biomed Intl Ltd. Logo

THC Biomed Intl Ltd.

THC.CN

(0.8)
Stock Price

0,02 CAD

-16.48% ROA

-74.64% ROE

-1.45x PER

Market Cap.

3.278.760,00 CAD

102.25% DER

0% Yield

-149.09% NPM

THC Biomed Intl Ltd. Stock Analysis

THC Biomed Intl Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

THC Biomed Intl Ltd. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.87x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-61.44%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-26.74%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 DER

The company has a high debt to equity ratio (102%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

THC Biomed Intl Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

THC Biomed Intl Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

THC Biomed Intl Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

THC Biomed Intl Ltd. Revenue
Year Revenue Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2014 0 0%
2015 0 0%
2016 500.000 100%
2017 59.876 -735.06%
2018 925.339 93.53%
2019 1.489.603 37.88%
2020 4.178.179 64.35%
2021 3.774.321 -10.7%
2022 3.339.997 -13%
2023 1.904.920 -75.34%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

THC Biomed Intl Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

THC Biomed Intl Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 254.338 100%
2010 643.383 60.47%
2011 1.613.653 60.13%
2012 75.705 -2031.5%
2014 196.922 61.56%
2015 1.874.093 89.49%
2016 767.851 -144.07%
2017 1.196.798 35.84%
2018 2.623.584 54.38%
2019 5.423.312 51.62%
2020 1.967.068 -175.71%
2021 1.686.731 -16.62%
2022 1.162.755 -45.06%
2023 617.588 -88.27%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

THC Biomed Intl Ltd. EBITDA
Year EBITDA Growth
2001 -136.593
2002 -117.216 -16.53%
2003 -236.445 50.43%
2004 -675.730 65.01%
2005 214.088 415.63%
2006 -750.723 128.52%
2007 -1.357.828 44.71%
2008 -8.912 -15135.95%
2009 -7.911 -12.65%
2010 2.316.366 100.34%
2011 -1.840.171 225.88%
2012 -571.335 -222.08%
2014 -200.836 -184.48%
2015 -1.925.761 89.57%
2016 -496.530 -287.84%
2017 790.985 162.77%
2018 -9.867.136 108.02%
2019 -11.982.238 17.65%
2020 1.220.462 1081.78%
2021 -4.954.043 124.64%
2022 -2.267.789 -118.45%
2023 -2.337.996 3%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

THC Biomed Intl Ltd. Gross Profit
Year Gross Profit Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2014 0 0%
2015 0 0%
2016 399.421 100%
2017 -85.835 565.34%
2018 467.222 118.37%
2019 1.502.417 68.9%
2020 3.243.964 53.69%
2021 -3.174.261 202.2%
2022 -1.029.647 -208.29%
2023 -1.481.600 30.5%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

THC Biomed Intl Ltd. Net Profit
Year Net Profit Growth
2001 -235.300
2002 -118.570 -98.45%
2003 -238.656 50.32%
2004 -684.958 65.16%
2005 -1.194.835 42.67%
2006 -2.365.055 49.48%
2007 -1.321.916 -78.91%
2008 -886.198 -49.17%
2009 -538.128 -64.68%
2010 -3.804.834 85.86%
2011 -2.381.350 -59.78%
2012 -8.114.516 70.65%
2014 -215.342 -3668.2%
2015 -3.062.056 92.97%
2016 -286.340 -969.38%
2017 -604.867 52.66%
2018 -12.458.908 95.15%
2019 -9.419.463 -32.27%
2020 -523.265 -1700.13%
2021 -6.782.177 92.28%
2022 -2.434.212 -178.62%
2023 -3.744.436 34.99%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

THC Biomed Intl Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 -2
2002 -1 0%
2003 0 0%
2004 0 0%
2005 -1 0%
2006 -1 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

THC Biomed Intl Ltd. Free Cashflow
Year Free Cashflow Growth
2001 -131.178
2002 -117.829 -11.33%
2003 -216.871 45.67%
2004 -751.584 71.14%
2005 -493.455 -52.31%
2006 -1.180.058 58.18%
2007 -1.389.975 15.1%
2008 -1.339.447 -3.77%
2009 -261.921 -411.39%
2010 -452.893 42.17%
2011 -3.248.660 86.06%
2012 -577.258 -462.77%
2014 -247.716 -133.03%
2015 -742.097 66.62%
2016 -1.057.246 29.81%
2017 -2.963.819 64.33%
2018 -7.563.162 60.81%
2019 -9.021.191 16.16%
2020 -1.312.027 -587.58%
2021 -1.379.557 4.9%
2022 -2.017.493 31.62%
2023 38.557 5332.49%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

THC Biomed Intl Ltd. Operating Cashflow
Year Operating Cashflow Growth
2001 -131.178
2002 -117.152 -11.97%
2003 -212.045 44.75%
2004 -406.584 47.85%
2005 -227.110 -79.03%
2006 -576.075 60.58%
2007 -609.931 5.55%
2008 -511.191 -19.32%
2009 -256.139 -99.58%
2010 -452.893 43.44%
2011 -1.233.007 63.27%
2012 -473.456 -160.43%
2014 -190.497 -148.54%
2015 -395.723 51.86%
2016 -898.294 55.95%
2017 -1.380.640 34.94%
2018 -2.431.542 43.22%
2019 -1.866.107 -30.3%
2020 114.933 1723.65%
2021 -1.010.247 111.38%
2022 -1.857.187 45.6%
2023 38.909 4873.16%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

THC Biomed Intl Ltd. Capital Expenditure
Year Capital Expenditure Growth
2001 0
2002 677 100%
2003 4.826 85.97%
2004 345.000 98.6%
2005 266.345 -29.53%
2006 603.983 55.9%
2007 780.044 22.57%
2008 828.256 5.82%
2009 5.782 -14224.73%
2010 0 0%
2011 2.015.653 100%
2012 103.802 -1841.82%
2014 57.219 -81.41%
2015 346.374 83.48%
2016 158.952 -117.91%
2017 1.583.179 89.96%
2018 5.131.620 69.15%
2019 7.155.084 28.28%
2020 1.426.960 -401.42%
2021 369.310 -286.39%
2022 160.306 -130.38%
2023 352 -45441.48%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

THC Biomed Intl Ltd. Equity
Year Equity Growth
2001 -57.673
2002 167.151 134.5%
2003 1.364.715 87.75%
2004 3.062.573 55.44%
2005 3.039.700 -0.75%
2006 2.973.187 -2.24%
2007 4.010.582 25.87%
2008 3.920.305 -2.3%
2009 3.514.340 -11.55%
2010 347.327 -911.82%
2011 7.657.551 95.46%
2012 -405.777 1987.13%
2014 -108.344 -274.53%
2015 -1.514.704 92.85%
2016 350.667 531.95%
2017 1.979.295 82.28%
2018 12.214.454 83.8%
2019 13.454.606 9.22%
2020 14.872.972 9.54%
2021 9.783.409 -52.02%
2022 6.933.131 -41.11%
2023 4.699.735 -47.52%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

THC Biomed Intl Ltd. Assets
Year Assets Growth
2001 22.473
2002 217.789 89.68%
2003 1.422.539 84.69%
2004 3.120.584 54.41%
2005 3.092.729 -0.9%
2006 3.006.317 -2.87%
2007 4.081.572 26.34%
2008 3.959.196 -3.09%
2009 3.614.615 -9.53%
2010 516.749 -599.49%
2011 8.009.783 93.55%
2012 43.361 -18372.32%
2014 473.181 90.84%
2015 1.267.427 62.67%
2016 1.600.973 20.83%
2017 6.963.292 77.01%
2018 14.479.923 51.91%
2019 18.058.337 19.82%
2020 21.774.654 17.07%
2021 17.396.441 -25.17%
2022 14.746.366 -17.97%
2023 13.721.302 -7.47%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

THC Biomed Intl Ltd. Liabilities
Year Liabilities Growth
2001 80.146
2002 50.638 -58.27%
2003 57.824 12.43%
2004 58.011 0.32%
2005 53.029 -9.39%
2006 33.130 -60.06%
2007 70.990 53.33%
2008 38.891 -82.54%
2009 100.275 61.22%
2010 169.422 40.81%
2011 352.232 51.9%
2012 449.138 21.58%
2014 581.525 22.77%
2015 2.782.131 79.1%
2016 1.250.306 -122.52%
2017 4.983.997 74.91%
2018 2.265.469 -120%
2019 4.603.731 50.79%
2020 6.901.682 33.3%
2021 7.613.032 9.34%
2022 7.813.235 2.56%
2023 9.021.567 13.39%

THC Biomed Intl Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.01
Price to Earning Ratio
-1.45x
Price To Sales Ratio
1.67x
POCF Ratio
-14.15
PFCF Ratio
-10.8
Price to Book Ratio
0.7
EV to Sales
4.02
EV Over EBITDA
-6.58
EV to Operating CashFlow
-34
EV to FreeCashFlow
-25.95
Earnings Yield
-0.69
FreeCashFlow Yield
-0.09
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.09
Graham NetNet
-0.05

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.1
ROE
-0.4
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
1
EBT Per Ebit
1.21
Ebit per Revenue
-1.23
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.27
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.58
Operating Profit Margin
-1.23
Pretax Profit Margin
-1.49
Net Profit Margin
-1.49

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0.31
Capex to Revenue
-0.04
Capex to Depreciation
-0.12
Return on Invested Capital
-0.18
Return on Tangible Assets
-0.16
Days Sales Outstanding
20.31
Days Payables Outstanding
186.59
Days of Inventory on Hand
368.38
Receivables Turnover
17.98
Payables Turnover
1.96
Inventory Turnover
0.99
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,03
Tangible Book Value per Share
0.03
Shareholders Equity per Share
0.03
Interest Debt per Share
0.03
Debt to Equity
1.02
Debt to Assets
0.35
Net Debt to EBITDA
-3.84
Current Ratio
0.41
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
1.02
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2642794.5
Debt to Market Cap
1.47

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

THC Biomed Intl Ltd. Dividends
Year Dividends Growth

THC Biomed Intl Ltd. Profile

About THC Biomed Intl Ltd.

THC Biomed Intl Ltd. produces and sells medical and recreational cannabis in Canada. It offers cannabis beverage shots, gummies, and biscuits under the THC KISS brand names, as well as pure cannabis sticks. The company was founded in 2012 and is headquartered in Kelowna, Canada.

CEO
Mr. John Miller
Employee
35
Address
2550 Acland Road
Kelowna, V1X 7L4

THC Biomed Intl Ltd. Executives & BODs

THC Biomed Intl Ltd. Executives & BODs
# Name Age
1 Jung Chun Hee
Co-Founder, Chief Financial Officer & Director
70
2 Mr. John Miller
President, Chief Executive Officer & Director
70

THC Biomed Intl Ltd. Competitors